Kendall Capital Management lifted its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 24.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,476 shares of the biopharmaceutical company’s stock after acquiring an additional 483 shares during the quarter. Kendall Capital Management’s holdings in Regeneron Pharmaceuticals were worth $930,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Bridger Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $30,000. HM Payson & Co. acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Barnett & Company Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 3,433.3% in the 4th quarter. Barnett & Company Inc. now owns 106 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 103 shares during the last quarter. Horan Capital Advisors LLC. acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $47,000. Finally, Simon Quick Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.
Shares of REGN traded down $11.32 during midday trading on Friday, reaching $345.28. The stock had a trading volume of 1,094,071 shares, compared to its average volume of 624,171. Regeneron Pharmaceuticals Inc has a 1-year low of $271.37 and a 1-year high of $442.00. The company’s fifty day simple moving average is $374.69 and its two-hundred day simple moving average is $324.13. The company has a market cap of $39.15 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.98 and a beta of 1.20. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.03 and a quick ratio of 3.27.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $5.13 by $1.54. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The business had revenue of $2.05 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same period last year, the business earned $5.87 EPS. The company’s revenue was up 23.2% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 20.26 earnings per share for the current year.
Regeneron Pharmaceuticals declared that its board has approved a share buyback plan on Tuesday, November 5th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.
REGN has been the topic of a number of research reports. Citigroup upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $340.00 to $420.00 in a report on Wednesday, November 6th. Bank of America initiated coverage on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 16th. They set a “neutral” rating and a $325.00 target price on the stock. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Monday, December 2nd. Piper Jaffray Companies set a $435.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 8th. Finally, SunTrust Banks initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 12th. They set a “hold” rating and a $360.00 target price on the stock. Thirteen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $390.11.
In related news, Chairman P Roy Vagelos sold 51,842 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $376.04, for a total value of $19,494,665.68. Following the transaction, the chairman now directly owns 412,140 shares of the company’s stock, valued at approximately $154,981,125.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $340.44, for a total transaction of $340,440.00. Following the completion of the transaction, the director now directly owns 10,323 shares in the company, valued at $3,514,362.12. The disclosure for this sale can be found here. Insiders sold a total of 109,543 shares of company stock worth $40,357,770 over the last 90 days. Company insiders own 11.84% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: Swap
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.